Anavex Life Sciences Corp (AVXL)

[boi568]

Kun Jin and Billy Dunn

I have confirmed that Kun Jin was the biostatistics team leader in the Aduhelm approval:

https://oversightdemocrats.house.gov/sites/democrats.oversight.house.gov/files/Final%20Document%20Packet%20-%20FDA%20Updated_Redacted.pdf

(See page 3/31)

But wait, there's more:

https://www.researchgate.net/publication/329776712_On_weighted_composite_scores_for_early_Alzheimer's_trials
https://www.researchgate.net/publication/339789920_Response_to_Counterpoint_to_Jin_et_al_On_weighted_composite_scores_for_early_Alzheimer's_trials_Pharm_Stat_182239-47_2019_DOI_101002pst1920

Jin and Billy Dunn were coauthors on a statistical analysis of Alzheimer's trial studies, and published together as recently as 2020.

This hire is a masterstroke by Missling. Not only is Jin the FDA's former lead expert on the Aduhelm submission, but he clearly has the professional trust and respect of the FDA's key decisionmaker, Billy Dunn. For all of you posters complaining that the FDA is corrupt and owned by Big Pharma -- move over, this is better. And cheaper, since Missling can pay in stock options instead of royalties.